Literature DB >> 24418575

MUC1: a novel metabolic master regulator.

Kamiya Mehla1, Pankaj K Singh2.   

Abstract

MUC1, a type I transmembrane protein, is significantly overexpressed and aberrantly glycosylated in tumors of epithelial origin. By virtue of its aberrant signaling due to loss of apical-basal polarity in cancer, MUC1 regulates the metabolite flux at multiple levels. Serving as a transcriptional co-activator, MUC1 directly regulates expression of metabolic genes. By regulating receptor tyrosine kinase signaling, MUC1 facilitates production of biosynthetic intermediates required for cell growth. Also, via direct interactions, MUC1 modulates the activity/stability of enzymes and transcription factors that directly regulate metabolic functions. Additionally, by modulation of autophagy, levels of reactive oxygen species, and metabolite flux, MUC1 facilitates cancer cell survival under hypoxic and nutrient-deprived conditions. This article provides a comprehensive review of recent literature on novel metabolic functions of MUC1.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer metabolism; Glycolysis; MUC1; Nutrient stress and carbon flux

Mesh:

Substances:

Year:  2014        PMID: 24418575      PMCID: PMC4045475          DOI: 10.1016/j.bbcan.2014.01.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  109 in total

1.  The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway.

Authors:  Min Fang; Zhirong Shen; Song Huang; Liping Zhao; She Chen; Tak W Mak; Xiaodong Wang
Journal:  Cell       Date:  2010-11-11       Impact factor: 41.582

2.  [Chromosomal changes in virus diseases, especially in varicella].

Authors:  J D Murken; D Vogt; B Baum
Journal:  Monatsschr Kinderheilkd       Date:  1970-06

Review 3.  Role of glutamine in cancer: therapeutic and imaging implications.

Authors:  Kartik N Rajagopalan; Ralph J DeBerardinis
Journal:  J Nucl Med       Date:  2011-06-16       Impact factor: 10.057

Review 4.  Programmed cell removal: a new obstacle in the road to developing cancer.

Authors:  Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2011-12-08       Impact factor: 60.716

5.  Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment.

Authors:  Yanique I Rattigan; Brijesh B Patel; Ellen Ackerstaff; George Sukenick; Jason A Koutcher; John W Glod; Debabrata Banerjee
Journal:  Exp Cell Res       Date:  2011-12-08       Impact factor: 3.905

6.  Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth.

Authors:  Shuhei Tanida; Kaoru Akita; Akiko Ishida; Yugo Mori; Munetoyo Toda; Mizue Inoue; Mariko Ohta; Masakazu Yashiro; Tetsuji Sawada; Kosei Hirakawa; Hiroshi Nakada
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

Review 7.  How cancer metabolism is tuned for proliferation and vulnerable to disruption.

Authors:  Almut Schulze; Adrian L Harris
Journal:  Nature       Date:  2012-11-15       Impact factor: 49.962

8.  Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-β.

Authors:  Robert Matthew Kottmann; Ajit A Kulkarni; Katie A Smolnycki; Elizabeth Lyda; Thinesh Dahanayake; Rami Salibi; Sylvie Honnons; Carolyn Jones; Nancy G Isern; Jian Z Hu; Steven D Nathan; Geraldine Grant; Richard P Phipps; Patricia J Sime
Journal:  Am J Respir Crit Care Med       Date:  2012-08-23       Impact factor: 21.405

Review 9.  Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases.

Authors:  W G Kaelin
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2011-11-16

10.  MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells.

Authors:  Michio Kosugi; Rehan Ahmad; Maroof Alam; Yasumitsu Uchida; Donald Kufe
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

View more
  38 in total

Review 1.  How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions?

Authors:  H Lincet; P Icard
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 2.  Novel roles for mucin 1 in the kidney.

Authors:  Mohammad M Al-Bataineh; Timothy A Sutton; Rebecca P Hughey
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-09       Impact factor: 2.894

3.  Muc1 is protective during kidney ischemia-reperfusion injury.

Authors:  Núria M Pastor-Soler; Timothy A Sutton; Henry E Mang; Carol L Kinlough; Sandra J Gendler; Cathy S Madsen; Sheldon I Bastacky; Jacqueline Ho; Mohammad M Al-Bataineh; Kenneth R Hallows; Sucha Singh; Satdarshan P Monga; Hanako Kobayashi; Volker H Haase; Rebecca P Hughey
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-29

Review 4.  Metabolic Regulation of Macrophage Polarization in Cancer.

Authors:  Kamiya Mehla; Pankaj K Singh
Journal:  Trends Cancer       Date:  2019-11-06

5.  Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.

Authors:  Hiroshi Kobayashi; Hitomi Sugimoto; Shunsuke Onishi; Kazutoshi Nakano
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

6.  Testing for the cytosine insertion in the VNTR of the MUC1 gene in a cohort of Italian patients with autosomal dominant tubulointerstitial kidney disease.

Authors:  Claudio Musetti; Deepak Babu; Ileana Fusco; Simona Mellone; Andrea Zonta; Marco Quaglia; Vincenzo Cantaluppi; Piero Stratta; Mara Giordano
Journal:  J Nephrol       Date:  2016-03-04       Impact factor: 3.902

7.  De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer.

Authors:  Saber Tadros; Surendra K Shukla; Ryan J King; Venugopal Gunda; Enza Vernucci; Jaime Abrego; Nina V Chaika; Fang Yu; Audrey J Lazenby; Lyudmyla Berim; Jean Grem; Aaron R Sasson; Pankaj K Singh
Journal:  Cancer Res       Date:  2017-08-15       Impact factor: 13.312

8.  Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).

Authors:  Jyoti D Patel; Ju-Whei Lee; David P Carbone; Henry Wagner; Anil Shanker; Maria Teresa P de Aquino; Leora Horn; Melissa L Johnson; David E Gerber; Jane Jijun Liu; Millie S Das; Mohammed Ali Al-Nsour; Christopher S R Dakhil; Suresh Ramalingam; Joan H Schiller
Journal:  Clin Lung Cancer       Date:  2020-06-12       Impact factor: 4.785

9.  MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer.

Authors:  Venugopal Gunda; Joshua Souchek; Jaime Abrego; Surendra K Shukla; Gennifer D Goode; Enza Vernucci; Aneesha Dasgupta; Nina V Chaika; Ryan J King; Sicong Li; Shuo Wang; Fang Yu; Tadayoshi Bessho; Chi Lin; Pankaj K Singh
Journal:  Clin Cancer Res       Date:  2017-07-18       Impact factor: 13.801

Review 10.  Mucin in cancer: a stealth cloak for cancer cells.

Authors:  Dong-Han Wi; Jong-Ho Cha; Youn-Sang Jung
Journal:  BMB Rep       Date:  2021-07       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.